More recent preclinical work has examined GHK-Cu in rodent models of pulmonary fibrosis, silicosis and airway remodelling, with oxidative stress and inflammatory signalling as the reported endpoints
Companies such as Sun Pharma, Dr
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF
Mitochondrial mass assessed by NAO staining in ( a ) HCT116 cells treated with TS-targeting therapies, ( b ) non-small cell lung cancer (NSCLC) cell lines treated with pemetrexed, ( c ) HCT116 cells treated with 5FU, FOLFOX (5FU+oxaliplatin), FOLFIRI (5FU + SN38), or single agent oxaliplatin and SN38, or ( d ) HCT116 cells treated 5FU Torin or rapamycin for 72 h